Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Generate plans $425M IPO to bankroll antibody’s phase 3 asthma trials

Generate plans $425M IPO to bankroll antibody’s phase 3 asthma trials

  • February 23, 2026

Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead antibody through respiratory disease trials.

Leave A Comment

Fields (*) Mark are Required